Tech Company Financing Transactions
Tarsa Therapeutics Funding Round
Tarsa Therapeutics secured a $10 million investment round on 8/13/2014. Backers included Oxford Finance and Square 1 Bank.
Transaction Overview
Company Name
Announced On
8/13/2014
Transaction Type
Debt
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8 Penn Center 1628 John F. Kennedy Blvd. 1400
Philadelphia, PA 19103
USA
Philadelphia, PA 19103
USA
Phone
Website
Email Address
Overview
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Brand
Chief Medical Officer
David Krause
Chief Scientific Officer
James Gilligan
VP - Regulatory Affairs
Nicholas LaBella
Browse more venture capital transactions:
Prev: 8/13/2014: Push Technology venture capital transaction
Next: 8/13/2014: Acupera venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs